Dr. reddy's laboratories enters into definitive agreement with citius pharmaceuticals, inc. to sell its rights to anti-cancer agent e7777 (denileukin diftitox)

Hyderabad, india & princeton, n.j.--(business wire)--dr. reddy's laboratories ltd. (bse: 500124, nse: drreddy, nyse: rdy, nseifsc: drreddy, along with its subsidiaries together referred to as “dr. reddy's”), announced that it has entered into a definitive agreement with citius pharmaceuticals, inc. (“citius”) pursuant to which it sold all of its rights to e7777 (an engineered il-2-diphtheria toxin fusion protein) and certain related assets. under the terms of agreement, dr. reddy's will receive
RDY Ratings Summary
RDY Quant Ranking